Vulvovaginal and ocular involvement and treatment in female patients with Stevens-Johnson syndrome and toxic epidermal necrolysis: A review

M Teresa Magone; Mary Maiberger; Janine Clayton; Helena Pasieka

doi:10.1016/j.ijwd.2021.08.012

Vulvovaginal and ocular involvement and treatment in female patients with Stevens-Johnson syndrome and toxic epidermal necrolysis: A review

Int J Womens Dermatol. 2021 Sep 2;7(5Part A):520-528. doi: 10.1016/j.ijwd.2021.08.012. eCollection 2021 Dec.

Authors

M Teresa Magone¹, Mary Maiberger², Janine Clayton^{1

3}, Helena Pasieka⁴

Affiliations

¹ Ophthalmology Consult Services Section, National Eye Institute, National Institutes of Health, Bethesda, Maryland.
² Department of Dermatology, Veterans Affairs Medical Center, Washington, DC.
³ Office of Research on Women's Health, National Institutes of Health, Bethesda, Maryland.
⁴ Uniformed Services University of Health Sciences, Bethesda, Maryland.

Abstract

Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) are serious adverse cutaneous drug reactions, characterized by epidermal detachment and mucous membrane involvement. SJS/TEN is more common in female patients, with unique findings in the ocular and vulvar regions. Early recognition and intervention, as well as long-term follow-up, are crucial to prevent devastating scarring and sequelae. This review examines the vulvar and ocular manifestations of SJS/TEN and describes the current treatment recommendations for female patients, requiring close consultation and collaboration among dermatology, ophthalmology, and gynecology.

Keywords: Stevens–Johnson syndrome; cutaneous drug eruption; dry eye; ocular-surface; toxic epidermal necrolysis; vulvar involvement.

Publication types

Review